<DOC>
	<DOCNO>NCT01570387</DOCNO>
	<brief_summary>This study seek enroll patient AL amyloidosis , treatment one standard melphalan chemotherapy-based regimen either recommend preference . Pomalidomide ( CC-4047 ) drug give mouth , change regulate function immune system . So , theory , may reduce prevent production amyloid protein . Pomalidomide currently FDA-approved AL Amyloidosis . Pomalidomide chemically similar thalidomide lenalidomide , drug approve FDA treatment patient multiple myeloma ( MM ) , disease similar AL Amyloidosis . Participants study receive pomalidomide dexamethasone . Phase I dose-escalation study dose escalation proceed 3 dose-levels accord standard rule dose level start sequentially complete evaluation occurrence dose-limiting toxicity . In Phase II portion , participant receive pomalidomide dexamethasone use define maximum tolerated dose .</brief_summary>
	<brief_title>A Phase I/II Trial Pomalidomide Dexamethasone Subjects With Previously-Treated AL Amyloidosis</brief_title>
	<detailed_description>Primary objective : Determine dose-limiting toxicity ( DLT ) maximal tolerate dose ( MTD ) pomalidomide combine dexamethasone subject previously- treated light-chain ( AL ) -amyloidosis Secondary objective : Determine follow MTD : - Hematological complete ( CR ) good partial ( VGPR ) partial ( PR ) rate - duration response - organ response - Time-to-event - Survival Exploratory study objective : To investigate relationship change level biomarkers BNP troponin I frequency specific adverse event occurrence DLT</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Understand voluntarily sign ICF . 2 . ≥18yrs old 3 . Able adhere study visit schedule protocol requirement . 4 . Biopsy proven tissue amyloid deposit positive fat aspirate 5 . Proof AL type ( b ) 6 . Measurable plasma cell dyscrasia ( b c follow require ) : 1 . Monoclonal protein serum urine immunofixation electrophoresis 2 . Plasmacytosis bone marrow ( &lt; 30 % plasma cell ) monoclonal stain kappa lambda lightchain isotype 3. dFLC 50mg/L ( dFLC=difference involve uninvolved serum free lightchain level ) 7 . Must receive ≥1 prior treatment AL amyloidosis , intensive chemotherapy autotransplant must ≥6 month prior enrollment study 8 . Must recover reversible side effect prior therapy ; permanent stable side effects/changes acceptable . Prior treatment AL amyloidosis chemotherapy , thalidomide , lenalidomide steroid exclusion 9 . SWOG PS ≤2 study entry 10 . Lab test result within range : d. Neutrophil ≥1.5 x10e9/L e. Platelets ≥100x10e9/L f. Total bilirubin &lt; 1.5mg/dL g. AST ( SGOT ) ALT ( SGPT ) &lt; 2xULN h. Serum creatinine &lt; 2.5mg/dL 11 . Disease free prior malignancy least 5yrs exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast . 12 . Females childbearing potential ( FCBP ) ( FCBP sexually mature woman undergone hysterectomy bilateral oophorectomy , naturally postmenopausal least 24 consecutive month ) must negative serum urine pregnancy test sensitivity ≥ 50 mIU/mL 1014 day prior ≤ 24 hour start pomalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , ≥ 28 day start take pomalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even vasectomy . All subject must counsel minimum every 28 day pregnancy precaution risk fetal exposure . 13 . Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( subject intolerant ASA may use warfarin low molecular weight heparin ) . 1 . Secondary familial amyloidosis 2 . Multiple myeloma ( ≥30 % plasma cell bone marrow biopsy specimen lytic bone lesion ) 3 . Cytotoxic chemo RT ≤4 week study entry follow baseline evaluation 4 . Symptomatic cardiac arrhythmia O2dependent restrictive cardiomyopathy 5 . Dialysisdependent 6 . Untreated uncontrolled infection . 7 . Serious medical condition , laboratory abnormality , psychiatric illness would prevent subject sign ICF . 8 . Pregnant breast feeding female ( lactate female must agree breast feed take pomalidomide ) . 9 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 10 . Use experimental drug therapy within 28 day baseline . 11 . Known intolerance steroid . 12 . Known hypersensitivity thalidomide lenalidomide 13 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 14 . Concurrent use anticancer agent treatment . 15 . Known HIV positivity exclusion , unless CD4 count &lt; 200/mcL and/or patient multidrug resistant HIV infection and/or concurrent AIDSdefining condition . HIV bDNA &lt; 75 copies/mL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>